Balchem vs Ingevity
BCPC and NGVT side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCPC and NGVT compare
Balchem is the larger company, worth 2.6 times as much as Ingevity ($5.5B against $2.1B).
On earnings, Balchem is cheaper: it trades at 32.6× trailing earnings, against 36.3× for Ingevity.
Balchem grew revenue faster over the last twelve months (9.4% versus −3.7% for Ingevity).
Balchem keeps more of each dollar of sales as profit, with a net margin of 15.4% compared with 5.3% at Ingevity.
Balchem pays a dividend yielding 0.55%; Ingevity does not pay one.
Balchem scores higher on the StockData Score (19 against 6 for Ingevity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCPC | NGVT |
|---|---|---|
| Size and price | ||
| Market cap | $5.5B | $2.1B |
| Share price | $173.14 | $61.72 |
| Change, 1 year | 10.1% | 25.6% |
| Change, 5 years | 3.4% | −21.7% |
| Beta (5Y) | 0.74 | 1.21 |
| Employees | 1,352 | 1,500 |
| StockData Score | ||
| Total score | 19 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 5 (better) | 3 |
| Health score | 6 (better) | 1 |
| Dividend score | 2 (better) | 0 |
| Valuation | ||
| P/E | 32.6× (better) | 36.3× |
| P/S | 5.0× | 1.9× (better) |
| P/B | 4.1× (better) | 33.7× |
| EV/EBITDA | 19.5× (better) | 23.1× |
| P/FCF | – | 17.3× |
| PEG | 2.42 | – |
| FCF yield | – | 5.8% |
| Fair value | $151.06 | $35.71 |
| Margin of safety | −14.6% (better) | −72.8% |
| Growth | ||
| Revenue growth (TTM) | 9.4% (better) | −3.7% |
| Revenue growth, 5Y average | 8.1% (better) | −0.81% |
| Net income growth (TTM) | 14.5% | – |
| EPS growth (TTM) | 16.2% | – |
| EPS growth, 5Y average | 12.8% | – |
| Profitability | ||
| Gross margin | 36.5% | 42.0% (better) |
| Operating margin | 20.7% | – |
| Net margin | 15.4% (better) | 5.3% |
| FCF margin | – | 10.8% |
| Return on equity | 13.0% | 59.5% (better) |
| Return on invested capital | 14.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | 18.18 (better) |
| Net debt / EBITDA | – | 7.68 |
| Current ratio | 2.47 (better) | 1.48 |
| Altman Z-score | 11.06 (better) | 2.29 |
| Piotroski F-score | 9 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.55% | – |
| Payout ratio | 18.0% | – |
| Years of dividend growth | 3 | – |
| Buyback yield | 2.3% | 7.4% (better) |
| Shareholder yield | 2.8% | 7.4% (better) |
| Ownership | ||
| Held by institutions | 91.3% | 102% |
| Held by insiders | 0.72% | 1.4% |
| Insider net buying, 12 months | −$2.2M | −$1.8M (better) |
| Short interest, % of float | 1.6% | 3.7% |
Go deeper
- BCPC stock overview
- BCPC income statement
- BCPC valuation and score
- NGVT stock overview
- NGVT income statement
- NGVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.